Loading companies…
Loading companies…
United States · Biotech · AI · Enterprise software
Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | $3.7M | Eisai Innovation — Role not disclosedFreeflow Ventures — Role not disclosedLifespan Vision Ventures — Role not disclosedSBI US Gateway Fund — Role not disclosedValuence Ventures — Role not disclosed |